Clinical Trial Update: Namenda (Memantine) for Non-motor Symptoms in Parkinson's Disease [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluated memantine (Namenda) for non-motor symptoms in Parkinson's disease; study completed with results posted in December 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Namenda (memantine)

Snippet

Sponsor: Baylor College of Medicine | Conditions: Parkinson's Disease | Phase 4 | Status: COMPLETED | Results posted: 2022-12-13